Answers are grounded in this paper and cite their sources.
Substance and alcohol use disorders (S/AUDs) are chronic, relapsing brain diseases with multifactorial etiologies, arising from complex interactions among genetic, environmental, and biological factors. Despite the availability of evidence-based treatments, clinical management remains challenging due to marked heterogeneity in disease presentation and treatment response. Advances in other medical fields, such as oncology and immunology, have demonstrated the value of biomarkers for patient stratification and personalized interventions. In addiction medicine, however, pharmacological and non-pharmacological treatments are largely generalized, with minimal consideration of individual characteristics, including sex differences. Women with S/AUDs often present with comorbid psychiatric conditions and experience unique pharmacokinetic and pharmacodynamic profiles influenced by hormonal fluctuations, which can affect medication efficacy, safety, and tolerability. Pharmacogenetic studies highlight the role of single nucleotide polymorphisms in drug-metabolizing enzymes, transporters, and receptors in shaping response to opioid and alcohol use disorder therapies. Emerging evidence further supports the potential of neurobiological and genetic markers to guide treatment with conventional medications and novel interventions, including psychedelic-assisted therapies. Collectively, these findings underscore the critical need to integrate precision medicine approaches in addiction treatment. Personalized, biomarker-informed strategies promise to optimize efficacy, reduce adverse effects, and improve patient-centered outcomes, offering a transformative framework for the management of S/AUDs.
No takes yet. Share an insight, caveat, or question.
Coppola et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: